Read More

Avanos Medical, Inc. Reports Preliminary Q4 And FY23 Financial Results; Revises Preliminary 2024 Revenue Outlook; Sees Q4 Revenue $170M-$173M Vs $179.27M Est.; FY23 Revenue $670M-$673M Vs $679.27M Est. ; FY24 Revenue $685M-$705M Vs $714.43M Est.

Avanos Medical, Inc. (NYSE:AVNS) today reported selected, unaudited preliminary financial results for the fourth quarter and full-year ended December 31, 2023 and revised its preliminary revenue outlook for

AVNS